Support a healthy pregnancy

An umbrella review inherits every weakness of what it reviews and adds no data of its own, so it can say the evidence base is poor without settling the question underneath it. Failing to demonstrate a link is not the same as demonstrating there is none, and the authors word their conclusion as the former. It covers autism and attention-deficit disorder only. Its search closed in September 2025, before the sibling-matched work published in 2026.

This is a precautionary ceiling drawn from a broad safety review, not a figure any trial in pregnant women produced. It describes a population rather than any particular pregnancy.

These are synthetic drugs given deliberately to ripen a baby's lungs, which is a different matter from living with a lot of one's own cortisol. What becomes of those children years later is still being studied. So is the safety of giving more than one course.

Five years cannot rule out a cancer that takes longer to appear, and the authors confine their conclusion to that window. The interval reaches a rate ratio of 1.13, so a modest increase is not excluded, only a large one. Almost everyone enrolled was a middle-aged or older adult in a heart-disease or bowel-polyp trial, so the reassurance reaches women of reproductive age by argument rather than by measurement.

The 4mg dose tested here is ten times what the general population is now told to take. The trial was stopped early once the result crossed its stopping rule, which tends to make an effect look larger than it is. Twenty-seven defects occurred in the whole trial, so the estimate is rough. Every woman enrolled had already had an affected pregnancy, so this says nothing about a first one.

A plateau is not a threshold. This models how long a level takes to stop rising, not how long until enough folate is present to protect an embryo, and those are different points. The 906 nmol/L target it is anchored to comes from observational Chinese data rather than a trial. Most of the pooled studies were in adults who were not pregnant, and red cell folate assays are notoriously hard to compare between laboratories.

None of this means 400 micrograms is the wrong number. It means nobody ran that trial. The Task Force reaffirmed its position rather than reviewing the evidence from scratch, and it gives a range without saying where in the range to sit. Its advice also addresses a country whose flour has been fortified since 1998, so the benefit of a tablet on top of that is not the benefit the old trials measured.

This is magnesium sulphate at monitored clinical doses through a vein; magnesium sold in capsules has never been shown to do anything for eclampsia risk. The trial ran across 33 countries with very different standards of care, so the background risk it was measured against varied from site to site. And the Cochrane review is built around this same trial, so the two are not independent of each other.

The reviewed trials establish the direction but not the size; how far the risk falls is not settled here. This is a different job from preventing a mother's seizures, working a different way, and the two should not be read as one use. And it applies to births that are very preterm, not to pregnancy generally.

The over-75 recommendation rests on a very small reduction in deaths, graded as high certainty but never translated into a number of lives. Most of the guideline's positions are worded as suggestions rather than recommendations, the wording used when certainty is low. The trials behind it used widely varying doses and often let participants keep taking their own vitamin D, so the right dose is left unresolved.

The clinical cases that established this used folic acid above 5mg a day in the 1940s and 1950s, roughly ten times a modern supplement and far above what fortified flour delivers, so it does not transfer straight to a 400 microgram tablet. The authors of the review say themselves that the modern evidence is correlative or from uncontrolled observation, and that their proposed mechanism has not been tested. They are also the group that proposed it.

The high-dose figure is deliberately absent here. The Canadian guideline states its tiers qualitatively rather than in milligrams, so no number can honestly be quoted from it, and an old trial dose is not a current recommendation. Both documents are graded syntheses of other people's work, resting partly on expert opinion where trials do not exist, and both address populations whose flour has been fortified since the 1990s.

None of this was randomised. These are before-and-after comparisons, so anything else that changed over the same years counts too: prenatal screening improved, supplement campaigns ran alongside the fortified flour, and registries differed in what they counted. What this design cannot do is separate the flour from the campaign that arrived with it.

A risk factor is not a diagnosis, and nothing here shows that carriers need a different supplement or a different dose. Pooled case-control genetic studies are prone to small-study effects and to population mismatch between cases and controls, so a significant pooled result is much weaker than the same result from trials. No odds ratio is reported, so the size of the association cannot be stated. The association did not hold in mixed populations, and nobody has explained why.

The 121 million figure is a model, not a count, built from country surveys of uneven quality and published with an 80% uncertainty range of 112.8 to 131.5 million. It also says nothing about who was or was not taking folic acid. The week-four timing comes from a clinical reference chapter that gives no study for it.

The review mixes randomised trials with observational studies. Its haemoglobin and ferritin figures came out with heterogeneity of 91% and 87%, which makes those pooled numbers too unstable to quote as point estimates. What is left is a benefit measured in blood tests and a diagnosis avoided, not in how the pregnancy or the baby turned out.

This concerns routine supplementation in women who are not anaemic, not the treatment of a diagnosed deficiency, where the case is different. The reviewers name the practical consequence themselves: international guidelines on this point disagree with each other. The same review mixes randomised trials with observational studies.

Of the 90 reports, 19 had enough detail to judge whether melatonin caused the problem, and the dose taken was often unknown. Reports show what was noticed, not how often it happens. Limits on melatonin supplements differ by country, from 0.3 mg in Belgium and Germany to under 2 mg in France.

Sibling comparison removes what families share but keeps only the families whose pregnancies differed, which is an unusual subset by construction, and it magnifies any error in recording who was exposed. Exposure came from antenatal notes and dispensing records in countries where paracetamol is sold freely, so a large share of real use is invisible: the Hong Kong figure of 43% exposed sits well below what surveys find. A null across these three diagnoses is not a clean bill of health for outcomes nobody measured. One author of each study declares payments from law firms or consulting in an area under active litigation.

Whether paracetamol in pregnancy raises autism or attention-deficit risk is still open. Comparing siblings best separates the drug from the family and finds no link; measuring it in cord blood best shows who was exposed and finds one.

An absence of proof is not proof of absence. Only five randomised trials of folate around conception exist at all, and just one was judged at low risk of bias. What this shows is that a question most people assume was settled by trial was put to a single small trial that could not settle it.

Whether folic acid prevents a first neural tube defect has never been put to a trial large enough to settle it. The one trial rests on six defects, all in one arm, and reviewers disagree on what that can carry.

This tested prevention during pregnancy in women who already had polycystic ovary syndrome, so it says nothing about inositol taken before conception for ovulation or cycles. All 13 sites were Dutch and 86.1% of participants reported White race. Baseline hyperandrogenism ran against the treated arm, 29.0% versus 18.5%.

Earlier, mostly Italian trials suggested myo-inositol in pregnancy roughly halved gestational diabetes; a later, adequately powered Dutch trial found no effect. The two are not of equal quality, which is why the null carries more weight.

There is no sibling or family-based control here, which is the design that dissolved associations of exactly this shape. Cord blood at delivery captures the hours and days before birth, so a gradient in late exposure is standing in for exposure across a whole pregnancy. Fever, infection and pain are themselves linked to these outcomes and are the reason the drug gets taken, which stratifying by recorded indication does not fix. This cohort is low-income, urban and enriched for preterm birth, and 26% of it had an attention-deficit diagnosis against a few percent in the general population.

Measuring paracetamol in cord blood is a better way to know who was exposed, and here it found a link. What it cannot do is separate the drug from what leads a family to take it; sibling studies can, and find none. The question stays open.

Homocysteine is a blood marker, not a birth outcome: this trial says nothing about whether either form prevents a neural tube defect. The 144 women were split across four arms, so each is small, and none was selected by genotype, which is the comparison the marketing claim actually turns on. A co-author affiliation with the maker of the methylated preparation is worth checking before the result is quoted in either direction.

Whether methylfolate beats plain folic acid in carriers of the MTHFR variant, a folate-activating enzyme gene, is not shown. The trial cited for it had no folic acid arm; the one that compared the two forms found no advantage.

This measures exposure, not harm. The authors say plainly that it does not show anyone was hurt, and call for the functional consequences to be investigated. It is one Toronto cohort of 368 women in a country with mandatory fortification, so these intakes are not typical of unfortified populations, and assay differences make the comparison with older, lower published values unreliable.

Four trials and 332 women leave enough room that a small real benefit could still be hiding inside the result. Cramps were defined and counted differently from trial to trial, which blunts any pooled figure. And this is cramps in pregnancy, not the ordinary night-time leg cramps most people mean.

The two trials used different magnesium compounds, so the split may be about which form sat in the capsule rather than about magnesium. Both groups improving by a third in the null trial points at expectation and the natural course of cramps doing much of the work. In the oldest positive trial, blood magnesium never actually rose, which makes it hard to credit magnesium with the improvement. And the trials counted cramps so differently that no single number can be drawn across them.